Chiusura precedente | 2,0000 |
Aperto | 2,0000 |
Denaro | 2,0900 x 800 |
Lettera | 2,5000 x 1400 |
Min-Max giorno | 2,0000 - 2,1398 |
Intervallo di 52 settimane | 1,8200 - 13,2000 |
Volume | |
Media Volume | 156.670 |
Capitalizzazione | 2,781M |
Beta (5 anni mensile) | 0,56 |
Rapporto PE (ttm) | N/D |
EPS (ttm) | -26,7500 |
Prossima data utili | 09 mag 2024 - 13 mag 2024 |
Rendimento e dividendo (futuro) | N/D (N/D) |
Data ex dividendo | N/D |
Stima target 1A | 16,00 |
- Key Catalysts ahead with Multiple Value Generating Readouts-- Expects to Release Phase 1/2 Data with Oral Fadraciclib -- Signals of Single-agent Efficacy with Oral Plogosertib -- Management to Host Conference Call at 4:30 pm EDT Today- BERKELEY HEIGHTS, N.J., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical leader in cell cycle checkpoint control developing innovative medicines based on cancer cell
BERKELEY HEIGHTS, N.J., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce second quarter 2023 financial results on Wednesday August 9, 2023. The Company will host a conference call and live webcast at 4:30 p.m. Eastern Daylight Time on the same day. Conference call information: Call: (800) 225-9448 / international call:
- Key Catalysts ahead with multiple Value Generating Readouts -- Expects to Report Phase 1/2 Data Releases with Oral Fadraciclib -- Advancing single-agent Efficacy with Differentiated Oral Plogosertib -- Adds to Balance Sheet with non-dilutive $4.7 million from R&D Tax Credit -- Management to Host Conference Call at 4:30 pm EDT Today - BERKELEY HEIGHTS, N.J., May 11, 2023 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceu